NEU · Neuren Pharmaceuticals Limited

20.21

AUD

-0.30 (-1.463%)

10/09/2026 04:10:04 PM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

AU$2.60B

78.40

EV/EBITDA

97

DIV Yield

0%

Franking

100%

MQV Rating

2Strong

As at 10/09/2026 04:10:04 PM

Price Chart

Description

Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the following segments: Commercial Products, and Research and Development. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Melbourne, Australia.

All-Companies
All-Consensus
GROWTH AUS
HALO 200
HALO Balance Sheet
HALO Momentum
HALO MQV SMALL
HALO Ords
HALO Small
Short Sold <-1 over the month

Key Fundamentals

EPS 3 yr Growth

15720.00%

EBITDA Margin

34.10%

Operating Cashflow

$125m

Free Cash Flow Return

35.70%

ROIC

8.70%

Interest Coverage

N/A

Quick Ratio

76.60

Performance

52 weeks range

Low 11 - 23.76

Trade Value (12mth)

AU$1,983,616.00

1 week

2.76%

1 month

-12.01%

YTD

8.46%

1 year

6.43%

All time high

25.95

Additional Data

Shares Outstanding (Fully Diluted)

127m

HALO Sector

Healthcare

Next Company Report Date

24-Feb-27

Next Ex Dividend Date

15-Sep-26

Next Dividend Pay Date

07-Oct-26

Reporting Currency

AUD

Short Sell (% of issue)

3.47

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Strong

Halo Model

Mqv

Strong

Garp

Neutral

Mqv Small

Very Strong

Momentum

Price

Strong

Earnings

Strong

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Strong

Balance Sheet

Very Strong

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

Date	Event
26 August 26ASXD
26 August 26ASXD
26 August 26ASXD
26 August 26ASXD
25 August 26ASXD

Key Stakeholders

Name	Title
Cameron Richard Pty Ltd.	Private Company
Stuart Andrew Pty Ltd.	Private Company
Trevor Donald Scott	Individual
Linwierik Super Pty Ltd.	Private Company
Smithley Super Pty Ltd.	Private Company